Immuron (IMRN) Cash from Investing Activities (2016 - 2024)
Immuron's quarterly Cash from Investing Activities came in at $35309.1 in Q4 2024, down 64.67% year-on-year from $99932.2 in Q1 2024, and down 64.67% quarter-over-quarter from $99932.2 in Q4 2023.
Immuron has reported Cash from Investing Activities for 8 years, with the latest figure at $35309.1 in Q4 2024.
- For the quarter ending Q4 2024, Cash from Investing Activities fell 64.67% year-over-year to $35309.1; the trailing twelve-month figure through Dec 2024 stood at -$2.5 million (up 1.43% YoY), and the FY2025 full-year result was -$2.9 million, down 985.46% from the prior year.
- Cash from Investing Activities for Q4 2024 stood at $35309.1, down from $99932.2 in the prior quarter.
- The five-year high for Cash from Investing Activities was $99932.2 in Q4 2023, with the low at -$2.6 million in Q4 2022.
- Average Cash from Investing Activities over 4 years is -$617157.2, with a median of $17504.0 recorded in 2020.
- Year-over-year, Cash from Investing Activities jumped 103.84% in 2023 and plunged 64.67% in 2024.
- Tracing IMRN's Cash from Investing Activities over 4 years: stood at -$301.0 in 2020, then sank by 864873.09% to -$2.6 million in 2022, then surged by 103.84% to $99932.2 in 2023, then sank by 64.67% to $35309.1 in 2024.
- The last three Cash from Investing Activities figures came in at $35309.1 (Q4 2024), $99932.2 (Q4 2023), and -$2.6 million (Q4 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.89 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 638.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -431.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -428.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Immuron | 1.27 Bn | 1.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 35,309.08 |
| Dec 31, 2024 | 35,309.08 |
| Dec 31, 2023 | 99,932.25 |
| Dec 31, 2023 | 99,932.25 |
| Dec 31, 2022 | -2.60 Mn |
| Dec 31, 2022 | -2.60 Mn |
| Dec 31, 2020 | -301.00 |
| Dec 31, 2020 | -301.00 |
| Dec 31, 2019 | -605.00 |
| Dec 31, 2019 | -605.00 |
| Dec 31, 2018 | 39.00 |
| Dec 31, 2018 | 39.00 |
| Dec 31, 2017 | -1,698.97 |
| Dec 31, 2017 | -1,698.97 |
| Dec 31, 2016 | 1,416.72 |
| Dec 31, 2016 | 1,416.72 |